Abstract
Paclitaxel (PTX, Taxol) has revolutionized cancer treatment in the past decade and is recognized as one of the biggest advances in oncology medicine. In spite of the good clinical efficacy shown by PTX, there is still a growing need to achieve better safety and pharmacokinetic profile of PTX in patients. The standard delivery modalities of intravenous infusion result in multiple side effects, and targeting of the drug to specific areas within the body can result in better efficacy and lower toxicity. Aerosol delivery of therapeutic agents has the potential of localizing the drugs specifically to the lung tissue, with a comparable or better pharmacokinetics as compared to intravenous, oral or intraperitoneal delivery. Aerosol delivery of PTX has not been studied extensively, however, it holds immense potential for improving the efficacy against lung tumors. Early pre-clinical studies in mice and dogs have shown good promise, both for pharmacokinetics of PTX, safety and efficacy in lung cancer models. This review looks at the still developing approach of aerosol delivery of PTX for lung cancer, documents the progress so far and the future directions that can bring this approach to clinical reality.
Keywords: taxoid derivates, lung cancer treatment:, aerosol delivery, paclitaxel
Current Cancer Drug Targets
Title: Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Volume: 3 Issue: 4
Author(s): Ajay Gautam and Nadezhda Koshkina
Affiliation:
Keywords: taxoid derivates, lung cancer treatment:, aerosol delivery, paclitaxel
Abstract: Paclitaxel (PTX, Taxol) has revolutionized cancer treatment in the past decade and is recognized as one of the biggest advances in oncology medicine. In spite of the good clinical efficacy shown by PTX, there is still a growing need to achieve better safety and pharmacokinetic profile of PTX in patients. The standard delivery modalities of intravenous infusion result in multiple side effects, and targeting of the drug to specific areas within the body can result in better efficacy and lower toxicity. Aerosol delivery of therapeutic agents has the potential of localizing the drugs specifically to the lung tissue, with a comparable or better pharmacokinetics as compared to intravenous, oral or intraperitoneal delivery. Aerosol delivery of PTX has not been studied extensively, however, it holds immense potential for improving the efficacy against lung tumors. Early pre-clinical studies in mice and dogs have shown good promise, both for pharmacokinetics of PTX, safety and efficacy in lung cancer models. This review looks at the still developing approach of aerosol delivery of PTX for lung cancer, documents the progress so far and the future directions that can bring this approach to clinical reality.
Export Options
About this article
Cite this article as:
Gautam Ajay and Koshkina Nadezhda, Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery, Current Cancer Drug Targets 2003; 3 (4) . https://dx.doi.org/10.2174/1568009033481912
DOI https://dx.doi.org/10.2174/1568009033481912 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Energy Intake and Expenditure Due to Habitual Physical Exercise
Current Pharmaceutical Design Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets VEGF Inhibitors and Prostate Cancer Therapy
Current Molecular Pharmacology The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?
Anti-Cancer Agents in Medicinal Chemistry Library of Synthetic Compounds Based on Pyrazole Unit: Design and Screening Against Breast and Colorectal Cancer
Letters in Drug Design & Discovery CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Current Medicinal Chemistry Current Treatment of Relapsed Ovarian Carcinoma
Current Cancer Therapy Reviews Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology What Does Systems Biology Mean for Drug Development?
Current Medicinal Chemistry Whole Organism Based Techniques and Approaches in Early Stage Oncology Drug Discovery-Patents and Trends
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Chronic Inflammatory-Modulating Potential of <i>Cassia auriculata</i> with Proinflammatory Cytokine IL-1beta and Its Anticancer Effect on Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Advances and Application of DNA-functionalized Nanoparticles
Current Medicinal Chemistry Space Radiation Dosimetry: Overview and Recent Developments
Recent Patents on Space Technology Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis
Mini-Reviews in Medicinal Chemistry